Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

NCT02090530 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2026-04-08

No results posted yet for this study

Summary

Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing

Conditions

Interventions

OTHER

Biospecimen collection

Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH
  • Ohio State University Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Sameek Roychowdhury, MD, PhD · Ohio State University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-04
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02090530 on ClinicalTrials.gov